利敏舒治疗婴幼儿过敏性湿疹临床疗效观察  

Clinical observation of Liminshu in treating 674 cases of Allergic Eczema in infants

作　　者：谈华龙 吴晓晨 Tan Hualong;Wu Xiaochen(Xiaogan Central Hospital,Xiaogan,Hubei 432000,China;Yankuang General Hospital,Zoucheng,Shandong273500,China)

机构地区：[1]孝感市中心医院,湖北孝感432000 [2]山东邹城兖矿总医院,山东邹城273500

出　　处：《医药前沿》2019年第1期26-28,共3页Journal of Frontiers of Medicine

摘　　要：目的:探讨利敏舒治疗婴幼儿过敏性湿疹的临床疗效.方法:选取2017年4月-2018年7月我院接诊婴幼儿过敏性湿疹患者674例纳入研究,依据随机数表法分为对照组、观察组,各337例.对照组给予丁酸氢化可的松治疗,观察组服用利敏舒治疗,比较两组疗效、血清炎性因子、免疫球蛋白指标及不良反应、复发率.结果:治疗后,观察组IL-4、IL-5指标降低,IL-2、IFN-γ指标升高,差异有统计学意义(P<0.05);治疗后两组患儿免疫球蛋白(IgG、IgM)指标降低,研究组低于对照组,差异有统计学意义(P<0.05);观察组总有效率94.9%(320/337)高于对照组79.8%(269/337),差异有统计学意义(P<0.05);观察组复发率8.6%(29/337)低于对照组的25.2%(85/337),差异有统计学意义(P<0.05);两组不良反应发生率比较[7.4%(25/337)vs7.7%(26/337)],差异无统计学意义(P>0.05).结论:利敏舒可有效降低婴幼儿过敏性湿疹患者炎症水平,降低复发率,提高治疗效果,且安全性较好,值得积极应用和推广.Objective To investigate the clinical efficacy of Liminshu in the treatment of allergic eczema in infants and young children.Methods 674 cases of patients with allergic eczema in infonts and young children from April 2017 to July 2018 were enrolled.All the patients were divided into control group and observation group according to the random number table method,with 337 cases in each group.The patients in the control group were treated with hydrocortisone butyrate,and the patients in the observation group were treated with Liminshu.The efficacy serum inflammatnry factors,immunoglobulin indexes,adverse reactions and recurrence rates of the two groups were compared.Results After treatment,the IL-4 and IL-5 indexes in the observation group decreased,and the IL-2 and IFN-y indexes increased(P V 0.05).After treatment,the levels of immunoglobulin(IgG,IgM)in the two groups were lower;and the study group was lower than the control group(P<0.05).The total effective rate of the observation group was 94.9%(320/337)higher than that of the control group(79.8%(269/337))(P<0.05).The recurrence rate of the observation group was 8.6%(29/337),which was lower than that of the control group(25.2%,85/337)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups[7.4%(25/337)vs 7.7%(26/337))(P>0.05).Conclusion Liminshu can effectively reduce the inflammation level of infants with allergic eczema,reduce the recurrence rate,improve the therapeutic effect,and has good safety.It is worthy of active application and promotion.

关 键 词：利敏舒 婴幼儿 过敏性湿疹 免疫球蛋白 炎性因子 

分 类 号：R758.23[医药卫生—皮肤病学与性病学]